cilostazol has been researched along with Hypertension in 16 studies
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Cilostazol is useful for the prevention of the recurrence of vascular events in patients with lacunar infarction, and is probably effective in high-risk patients with diabetes and/or hypertension." | 5.13 | Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study. ( Fukuuchi, Y; Gotoh, F; Hirai, S; Itoh, E; Matsuda, T; Nishimaru, K; Ohashi, Y; Otomo, E; Sawada, T; Shinohara, Y; Terashi, A; Tohgi, H; Yamaguchi, T, 2008) |
| " Sex-specific odds ratios of age, diabetes mellitus (DM), hypertension (HTN), coronary artery disease (CAD), cerebral vascular accident (CVA), or using cilostazol for LEA or PRP were explored." | 3.77 | Determinants of lower extremity amputation or revascularization procedure in patients with peripheral artery diseases: a population-based investigation. ( Chen, JJ; Lee, CH; Liau, CS; Lin, LY, 2011) |
| "Cilostazol (CILO), a selective inhibitor of phosphodiesterase 3 with potent antithrombotic property, has been shown to have a vasculoprotective effect in atherosclerosis animal models due to its potential anti-inflammatory and antioxidant actions." | 3.76 | Vasculoprotective effect of cilostazol in aldosterone-induced hypertensive rats. ( Hirata, Y; Hirono, Y; Sakurada, M; Sekizawa, N; Suzuki, N; Yoshimoto, T, 2010) |
| "Pretreatment with cilostazol (100 mg/kg) significantly reduced infarct size." | 1.36 | Cilostazol, a phosphodiesterase inhibitor, attenuates photothrombotic focal ischemic brain injury in hypertensive rats. ( Hashimoto, A; Ito, H; Matsumoto, Y; Miyakoda, G; Yao, H, 2010) |
| "Cilostazol was then added in a cumulative manner (680-2,720 microg/L), and the tension generated was recorded." | 1.33 | Effects of cilostazol on human venous smooth muscle. ( Becker, RW; Kline, RA; Lusis, E; Sohn, RL, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 9 (56.25) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Reddy, SS | 1 |
| Agarwal, H | 1 |
| Barthwal, MK | 1 |
| Shinohara, Y | 1 |
| Gotoh, F | 1 |
| Tohgi, H | 1 |
| Hirai, S | 1 |
| Terashi, A | 1 |
| Fukuuchi, Y | 1 |
| Otomo, E | 1 |
| Itoh, E | 1 |
| Matsuda, T | 1 |
| Sawada, T | 1 |
| Yamaguchi, T | 1 |
| Nishimaru, K | 1 |
| Ohashi, Y | 1 |
| Ito, H | 1 |
| Hashimoto, A | 1 |
| Matsumoto, Y | 1 |
| Yao, H | 1 |
| Miyakoda, G | 1 |
| Sakurada, M | 1 |
| Yoshimoto, T | 1 |
| Sekizawa, N | 1 |
| Hirono, Y | 1 |
| Suzuki, N | 1 |
| Hirata, Y | 1 |
| Chen, JJ | 1 |
| Lee, CH | 1 |
| Lin, LY | 1 |
| Liau, CS | 1 |
| Bertelli, L | 1 |
| Amato, A | 1 |
| Sangiorgi, GM | 1 |
| Asplund, CA | 1 |
| O'Connor, FG | 1 |
| Becker, RW | 1 |
| Lusis, E | 1 |
| Sohn, RL | 1 |
| Kline, RA | 1 |
| Agrawal, NK | 1 |
| Maiti, R | 1 |
| Dash, D | 1 |
| Pandey, BL | 1 |
| Lipsitz, EC | 1 |
| Kim, S | 1 |
| Falconer, TM | 1 |
| Eikelboom, JW | 1 |
| Hankey, GJ | 1 |
| Norman, PE | 1 |
| Yang, R | 1 |
| Powell-Braxton, L | 1 |
| Ogaoawara, AK | 1 |
| Dybdal, N | 1 |
| Bunting, S | 1 |
| Ohneda, O | 1 |
| Jin, H | 1 |
| Nomura, S | 1 |
| Imamura, A | 1 |
| Okuno, M | 1 |
| Kamiyama, Y | 1 |
| Fujimura, Y | 1 |
| Ikeda, Y | 1 |
| Fukuhara, S | 1 |
| Hiatt, WR | 2 |
| Nehler, MR | 1 |
| Regensteiner, JG | 1 |
3 reviews available for cilostazol and Hypertension
| Article | Year |
|---|---|
Management of peripheral arterial disease in the elderly: focus on cilostazol.
Topics: Aged; Cilostazol; Diabetic Angiopathies; Dose-Response Relationship, Drug; Dyslipidemias; Humans; Hy | 2008 |
Peripheral arterial disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cilostazol; Diabetes Complications; Diabetes Mellitus; Dis | 2001 |
Current medical therapies for patients with peripheral arterial disease: a critical review.
Topics: Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Cardiovascular Diseases; Cilostazol; Dia | 2002 |
2 trials available for cilostazol and Hypertension
| Article | Year |
|---|---|
Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study.
Topics: Aged; Brain Ischemia; Cerebral Infarction; Cilostazol; Diabetes Complications; Double-Blind Method; | 2008 |
Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients.
Topics: Anti-Inflammatory Agents; Antioxidants; Blood Sedimentation; C-Reactive Protein; Cardiovascular Dise | 2007 |
11 other studies available for cilostazol and Hypertension
| Article | Year |
|---|---|
Cilostazol ameliorates heart failure with preserved ejection fraction and diastolic dysfunction in obese and non-obese hypertensive mice.
Topics: Angiotensin II; Animals; Biomarkers; Biopsy; Blood Pressure; Cilostazol; Diastole; Disease Models, A | 2018 |
Peripheral artery disease. Heart health for your legs.
Topics: Angioplasty, Balloon; Atherosclerosis; Cilostazol; Diabetes Complications; Exercise; Fibrinolytic Ag | 2014 |
Cilostazol, a phosphodiesterase inhibitor, attenuates photothrombotic focal ischemic brain injury in hypertensive rats.
Topics: Animals; Aspirin; Brain Ischemia; Cells, Cultured; Cerebrovascular Circulation; Cilostazol; Clopidog | 2010 |
Vasculoprotective effect of cilostazol in aldosterone-induced hypertensive rats.
Topics: Aldosterone; Animals; Aorta; Atherosclerosis; Blood Pressure; Chemokine CCL2; Cilostazol; Disease Mo | 2010 |
Determinants of lower extremity amputation or revascularization procedure in patients with peripheral artery diseases: a population-based investigation.
Topics: Aged; Amputation, Surgical; Cilostazol; Coronary Artery Disease; Female; Humans; Hypertension; Logis | 2011 |
Treatment of superficial and profunda femoral artery bifurcation lesions: still a procedure only for surgeons?
Topics: Aged; Atherosclerosis; Catheters; Chronic Disease; Cilostazol; Coronary Artery Bypass; Coronary Arte | 2012 |
An unusual cause of exertional leg pain.
Topics: Adult; Anticoagulants; Antihypertensive Agents; Cilostazol; Drug Therapy, Combination; Femoral Arter | 2004 |
Effects of cilostazol on human venous smooth muscle.
Topics: Cilostazol; Diabetes Mellitus; Dose-Response Relationship, Drug; Humans; Hypercholesterolemia; Hyper | 2005 |
Antithrombotic therapy in peripheral arterial disease.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Cilostazol; Clopidogrel; Comorbidity; Diabetic Angiopathie | 2008 |
Hypertension and endothelial dysfunction in apolipoprotein E knockout mice.
Topics: Age Factors; Animals; Apolipoproteins E; Arteriosclerosis; Cholesterol; Cilostazol; Endothelium, Vas | 1999 |
Platelet-derived microparticles in patients with arteriosclerosis obliterans: enhancement of high shear-induced microparticle generation by cytokines.
Topics: Aged; Arteriosclerosis Obliterans; Biomarkers; Blood Platelets; Blood Vessel Prosthesis Implantation | 2000 |